People did need ample time to be able to transition to an alternative therapy.

Patent litigation has been amicably resolved and the parties have agreed to dismiss the patent claims.

The cases that were cited by FDA were not new.

We continue to have a robust pipeline at Abbott. There are a number of exciting things coming up...

This is the way we're going for patients with HIV (who are) starting therapy for the first time. It's becoming very easy and safe and effective.

These findings reiterate our contention that chronic stroke patients benefit from CI therapy, regardless of the length of time that has passed since the onset of the stroke.